Oxford-AstraZeneca vaccine technology used to design jab that could treat cancer


The technology used in the Oxford-AstraZeneca COVID jab has been used to design a vaccine that could help treat cancer, scientists say.

Using the same viral vector vaccine technology as the Oxford jab, researchers have designed a two-dose vaccine they hope can target tumours in humans.

When tested in mice, the vaccine increased the numbers of anti-tumour T cells that attack cancerous growths, helping to increase survival rates.

In order to create the treatment, scientists designed their vaccine to target two MAGE-type proteins that are present on the surface of many types of cancer cells.

It is hoped the jab can be used in humans alongside cancer immunotherapy where a patient’s T cells are turned against tumours.

A clinical trial will now take place in people with non-small cell lung cancer later this year.


By Justgivemepositivenews Team